Cellectis (CLLS) Launches $22M Follow-On Offering streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
• Maximum Potential Dilution of Approximately 23.04%, Based on Share Capital of Cellectis as of September 30, 2022 NEW YORK, Jan. 04, 2023 Cellectis S.A. , a clinical-stage. | January 4, 2023
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
UCART22: anti-tumor activity observed in 60% of patients at DL3 using FCA lymphodepletionUCART123: 25% of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a. | December 13, 2022